325 Participants Needed

Anlotinib for Alveolar Soft Part Sarcoma

(APROMISS Trial)

Recruiting at 22 trial locations
MC
JC
Overseen ByJudy Clinical Trial Manager
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Advenchen Laboratories, LLC
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.

Research Team

PC

Paul CEO

Principal Investigator

Advenchen Laboratories, LLC

Eligibility Criteria

Adults with advanced alveolar soft part sarcoma (ASPS) can join this trial. They may or may not have had previous treatments but must show disease progression. Key requirements include good organ function, no severe diseases, controlled blood pressure, and agreement to use contraception. Those with certain prior treatments or conditions like active brain metastases or recent major surgeries cannot participate.

Inclusion Criteria

Platelet count > 100,000 cells/mm3, hemoglobin > 9 g/dL, absolute neutrophil count > 1,500 cells/mm3
My blood clotting tests are within normal limits, or I'm on blood thinners with no prior clotting issues.
Females of childbearing potential must have a negative pregnancy test (by serum beta- HCG) within 7 days prior to the start of treatment.
See 25 more

Exclusion Criteria

I do not have serious, uncontrolled infections.
I do not have any severe and uncontrolled diseases.
Untreated psychiatric disorders
See 33 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive AL3818 or IV dacarbazine in 21-day cycles until disease progression or unacceptable toxicity

Up to 48 months
Every 21 days (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

Treatment Details

Interventions

  • Anlotinib
  • Dacarbazine
Trial OverviewThe trial is testing the safety and effectiveness of a drug called AL3818 (anlotinib) for ASPS compared to IV dacarbazine in leiomyosarcoma (LMS) or synovial sarcoma (SS), which are no longer being recruited. Two-thirds will receive anlotinib; one-third will get dacarbazine.
Participant Groups
6Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Indication C: SS AL3818 Arm - CLOSEDExperimental Treatment1 Intervention
Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Group II: Indication B: LMS AL3818 Arm - CLOSEDExperimental Treatment1 Intervention
Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Group III: Indication A: ASPS AL3818 Arm - CLOSEDExperimental Treatment1 Intervention
All subjects with ASPS will be assigned to the open-label AL3818 arm to receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Group IV: Indication C: SS Dacarbazine Arm - CLOSEDActive Control1 Intervention
Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m\^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
Group V: Indication B: LMS Dacarbazine Arm - CLOSEDActive Control1 Intervention
Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m\^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
Group VI: Indication D: LMS AL3818 or Placebo Arm - CLOSEDPlacebo Group1 Intervention
Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or placebo in a double-blind manner. AL3818 or placebo will be administrated as one 12 mg capsule orally once daily in 21-day cycles for 14 days on treatment (Days 1-14) and 7 days off treatment (Days 15-21).

Find a Clinic Near You

Who Is Running the Clinical Trial?

Advenchen Laboratories, LLC

Lead Sponsor

Trials
6
Recruited
850+